Health Related Quality of Life Using Serum Testosterone as the Trigger to Re-Dose Long Acting Depot Luteinizing Hormone-Releasing Hormone Agonists in Patients with Prostate Cancer

This publication has 10 references indexed in Scilit:

• Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer
  Journal of Urology, 2002
• Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
  Urology, 2000
• Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making
  Urology, 2000
• FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHM
  Journal of Urology, 2000
• Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment
  Urology, 1999
• TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATION
  Journal of Urology, 1998
• Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial
  Urology, 1995
• The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups
  Medical Care, 1994
• The MOS 36-ltem Short-Form Health Survey (SF-36)
  Medical Care, 1992
• Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
  Proceedings of the National Academy of Sciences, 1982